| Literature DB >> 35453353 |
Yousef M Alharbi1, Sally S Sakr2,3, Saleh M Albarrak1, Tariq I Almundarij1, Hassan Barakat2,4, Mohamed F Y Hassan2,5.
Abstract
Antioxidative, antidiabetic, and hypolipidemic properties of probiotic-enriched fermented camel milk (FCM) combined with Salvia officinalis L. leaves hydroalcoholic extract (SOHE) in streptozotocin-induced diabetes in rats were investigated. Phytochemicals analysis and antioxidant capacity indicated that S. officinalis contained high phenolics with super antioxidant activity. Subsequently, HPLC analysis demonstrated 13 phenolic acids and 14 flavonoids in considerable amounts with ferulic acid and resveratrol as predominant, respectively. The antidiabetic and hypolipidemic properties of FCM and SOHE were examined in a designed animal model consisting of seven treated groups for four weeks. There was a negative group (G1); the positive group (G2) received a single dose (50 mg kg-1) of streptozotocin (STZ) by intraperitoneal injection (i.p.); in G3, diabetic rats (DRs) orally received 5 mL FCM kg-1 daily; in G4, DRs orally received 50 mg GAE SOHE kg-1 daily; in G5, DRs orally received 5 mL FCM contains 25 mg GAE SOHE kg-1 daily; in G6, DRs orally received 5 mL FCM contains 50 mg GAE SOHE kg-1 daily; in G7, DRs orally received 50 mg metformin kg-1 daily. Combining FCM with SOHE at 25 or 50 mg kg-1 exhibited a synergistic effect in significantly lowering random blood glucose (RBG), fasting blood glucose (FBG), and improved weight gain recovery %. The hypolipidemic effect of FCM + 50 mg GAE SOHE kg-1 was significantly higher than using FCM or SOHE individually, and attenuation in triglycerides (TG), total cholesterol (CHO), and high- and low-density lipoproteins (HDL and LDL), and very-low-density lipoproteins (VLDL) was remarked. Combining FCM with SOHE at 25 or 50 mg kg-1 ameliorated liver and kidney functions better than individual uses of FCM, SOHE, or metformin. Interestingly, FCM with 50 mg SOHE kg-1 presented significant improvement in the activity of antioxidant enzymes, reduced glutathione (GSH), catalase (CAT), superoxide dismutase (SOD), and a substantial reduction in malonaldehyde (MDA) levels with 53.75%, 89.93%, 63.06%, and 58.69% when compared to the STZ group (G2), respectively. Histopathologically, administrating FCM + 25, 50 mg SOHE kg-1 or 50 mg kg-1 metformin showed a normal histological structure of both islets of Langerhans cells and acini. In conclusion, combining FCM with SOHE presented synergistic and therapeutical efficacy. It could be beneficial and profitable for controlling diabetes mellitus complications and protecting against oxidative stress.Entities:
Keywords: Salvia officinalis; antidiabetic; fermented camel milk; hypolipidemic efficiency; oxidative stress; probiotics
Year: 2022 PMID: 35453353 PMCID: PMC9025180 DOI: 10.3390/antiox11040668
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Total phenolic content, total carotenoids, total flavonoids, total flavonols, and relative potential antioxidant activities of S. officinalis leaves (mean ± SE), n = 6.
| Item |
|
|---|---|
| TPC (mg GAE g−1) | 102.81 ± 2.14 |
| TC (µg g−1) | 4.11 ± 0.73 |
| TF (mg QE g−1) | 37.57 ± 1.98 |
| TFL (mg QE g−1) | 53.87 ± 0.91 |
| DPPH (µmol of TE g−1) | 337.62 ± 4.15 |
| ABTS (µmol of TE g−1) | 374.31 ± 3.48 |
| β-CB * (RAA) % | 63.27 ± 3.25 |
| CA (mg g−1) | 71.21 ± 3.17 |
*: relatively calculated based on BHA as 100%, RAA: relative antioxidant activity.
Quantitative analysis of phenolic compounds in S. officinalis leaves (mean ± SE), n = 3.
| Item | No. | Compound | SOHE (mg 100 g−1) |
|---|---|---|---|
| Phenolic acids | 1 | Pyrogallol | - |
| 2 | Quinol | - | |
| 3 | 3-Hydroxytyrosol catechol | - | |
| 4 | 23.28 ± 1.25 | ||
| 5 | Caffeic acid | 39.15 ± 2.17 | |
| 6 | Chlorogenic acid | 1.27 ± 0.21 | |
| 7 | Cinnamic acid | 28.34 ± 3.27 | |
| 8 | Ellagic acid | 5.57 ± 0.78 | |
| 9 | Vanillic acid | 49.73 ± 4.58 | |
| 10 | Ferulic acid | 814.17 ± 14.87 | |
| 11 | Gallic acid | 1.17 ± 0.14 | |
| 12 | 7.08 ± 0.87 | ||
| 13 | 12.27 ± 1.59 | ||
| 14 | Benzoic acid | 89.37 ± 5.47 | |
| 15 | Rosmarinic acid | 13.35 ± 2.14 | |
| 16 | Syringic acid | 5.09 ± 1.85 | |
| Flavonoids | 1 | Catechin | 0.25 ± 0.03 |
| 2 | Epicatechin | 98.12 ± 4.17 | |
| 3 | Kaempferol | 356.52 ± 12.01 | |
| 4 | Myricetin | 18.81 ± 3.27 | |
| 5 | Naringin | 18.18 ± 2.71 | |
| 6 | Hispidulin | 13.17 ± 2.07 | |
| 7 | Cirsimaritin | 89.43 ± 5.13 | |
| 8 | Quercetin | 91.07 ± 2.64 | |
| 9 | Luteolin-7-O-glucoside | 25.18 ± 3.27 | |
| 10 | Luteolin | 87.12 ± 1.78 | |
| 11 | Rutin | 19.67 ± 3.17 | |
| 12 | apigenin | 97.17 ± 1.89 | |
| 13 | Chrysin | 102.57 ± 3.18 | |
| 14 | Resveratrol | 1876.95 ± 23.49 |
SOHE: S. officinalis hydroalcoholic extraction, phenolic acids were identified at 28 nm, and flavonoids were identified at 365 nm, -: Not detected.
Effect of probiotic-enriched fermented camel milk (FCM) combined with S. officinalis on weight gain, RBG, and FBG in STZ-induced diabetes in rats.
| Groups | Weight Gain % | RBG | FBG | |||
|---|---|---|---|---|---|---|
| Weak-2 | Weak-4 | Weak-0 | Weak-2 | Weak-4 | ||
| G1 | 29.59 ± 1.68 a | 42.60 ± 0.48 a | 100.17 ± 2.23 d | 104.67 ± 1.87 e | 104.67 ± 1.83 g | 73.07 ± 4.70 d |
| G2 | 1.72 ± 0.07 d | 2.58 ± 0.16 d | 341.50 ± 17.83 bc | 399.33 ± 8.17 a | 291.67 ± 16.84 a | 201.74 ± 10.93 a |
| G3 | 17.16 ± 1.02 b | 27.25 ± 1.43 b | 358.17 ± 14.26 ab | 316.67 ± 17.26 b | 264.00 ± 5.45 b | 130.25 ± 9.70 b |
| G4 | 11.66 ± 4.82 c | 15.62 ± 1.07 c | 344.50 ± 13.45 b | 281.17 ± 11.12 c | 187.67 ± 11.44 c | 113.35 ± 37.13 bc |
| G5 | 12.36 ± 1.34 c | 17.92 ± 1.17 c | 378.67 ± 12.95 a | 289.83 ± 14.73 cb | 168.17 ± 4.32 d | 107.50 ± 14.41 bc |
| G6 | 29.36 ± 2.69 a | 29.18 ± 1.14 b | 357.83 ± 23.98 ab | 208.67 ± 24.37 d | 133.00 ± 4.50 f | 103.82 ± 7.41 bc |
| G7 | 23.68 ± 3.57 a | 26.32 ± 2.34 b | 320.33 ± 16.99 bc | 174.83 ± 13.98 d | 159.33 ± 3.09 e | 101.09 ± 6.17 bc |
G1–G7: Experimental groups see materials and methods; Section 2.6, RBG: Random blood glucose, FBG: Fasting blood glucose level measured in blood serum of 12-h fasted rats, a, b, c, d, e, f and g: There is no significant difference (p > 0.05) between any two means, within the same column have the same superscripted letters.
Effect of probiotic-enriched FCM combined with S. officinalis on lipid profile and Atherogenic index in STZ-induced diabetes in rats.
| Groups | Lipid Profile Parameters | |||||
|---|---|---|---|---|---|---|
| TG | CHO | HDL-CHO | LDL-CHO | VLDL-CHO | AI | |
| G1 | 50.32 ± 3.12 b | 106.22 ± 8.87 b | 42.39 ± 4.64 b | 53.76 ± 3.10 bc | 10.06 ± 0.88 c | 0.10 ± 0.21 b |
| G2 | 97.92 ± 4.86 a | 176.36 ± 14.95 a | 32.61 ± 3.23 d | 124.16 ± 6.59 a | 19.58 ± 1.37 a | 0.50 ± 0.18 a |
| G3 | 62.70 ± 4.59 b | 119.87 ± 7.17 b | 39.13 ± 3.07 bc | 68.20 ± 8.29 b | 12.54 ± 1.30 b | 0.21 ± 0.14 b |
| G4 | 57.84 ± 3.57 b | 108.22 ± 10.87 b | 43.48 ± 5.81 b | 53.18 ± 9.99 bc | 11.57 ± 1.01 b | 0.22 ± 0.32 b |
| G5 | 49.38 ± 6.10 b | 108.97 ± 5.00 b | 45.65 ± 3.02 b | 53.44 ± 3.39 bc | 9.87 ± 1.73 bc | 0.01 ± 0.29 c |
| G6 | 47.56 ± 4.59 b | 98.87 ± 5.52 b | 55.43 ± 5.74 a | 34.13 ± 4.51 c | 9.31 ± 1.48 bc | −0.07 ± 0.21 d |
| G7 | 55.33 ± 5.48 b | 113.56 ± 5.32 b | 38.04 ± 4.10 c | 64.45 ± 4.11 b | 11.07 ± 1.55 b | 0.16 ± 0.31 b |
G1–G7: Experimental groups see materials and methods; Section 2.6, TG: Triglycerides, CHO: Total cholesterols, HDL-CHO: High-density lipoprotein-cholesterols, LDL-CHO: Low-density lipoprotein-cholesterols, VLDL-CHO: Very low-density lipoprotein-cholesterols, AI: Atherogenic index, a, b, c and d: There is no significant difference (p > 0.05) between any two means within the same column with the same superscripted letters.
Effect of probiotic-enriched FCM combined with S. officinalis on liver functions in STZ-induced diabetes in rats.
| Groups | Liver’s Functions | ||||
|---|---|---|---|---|---|
| ALT (U L−1) | AST(U L−1) | ALP(U L−1) | T. Bili (mg dL−1) | D. Bili (mg dL−1) | |
| G1 | 42.99 ± 1.98 bc | 95.53 ± 5.03 c | 74.61 ± 3.93 b | 0.85 ± 0.01 c | 0.23 ± 0.04 b |
| G2 | 66.53 ± 4.94 a | 133.37 ± 5.31 a | 100.03 ± 3.01 a | 1.44 ± 0.08 a | 0.36 ± 0.08 a |
| G3 | 51.40 ± 1.01 b | 108.99 ± 8.14 b | 85.12 ± 6.36 b | 0.88 ± 0.01 c | 0.26 ± 0.05 ab |
| G4 | 47.13 ± 3.12 b | 102.81 ± 4.10 bc | 73.75 ± 1.91 c | 1.07 ± 0.12 bc | 0.21 ± 0.03 b |
| G5 | 45.48 ± 2.61 bc | 94.65 ± 5.28 c | 74.44 ± 1.75 c | 1.14 ± 0.05 b | 0.24 ± 0.04 b |
| G6 | 39.69 ± 4.15 c | 92.45 ± 6.51 c | 69.82 ± 2.40 c | 1.14 ± 0.05 b | 0.23 ± 0.04 b |
| G7 | 43.83 ± 2.94 bc | 101.14 ± 2.95 bc | 78.99 ± 2.31 b | 0.92 ± 0.08 c | 0.26 ± 0.04 ab |
a, b and c: No significant difference (p > 0.05) between any two means within the same column have the same superscripted letters. ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, ALP: Alkaline phosphatase, T. Bili: Total bilirubin, D. Bili: Direct bilirubin.
Effect of probiotic-enriched FCM combined with S. officinalis on kidneys’ functions in STZ-induced diabetes in rats.
| Group | Kidneys’ functions | |||||
|---|---|---|---|---|---|---|
| T. Protein | Albumin | Globulin | Createnine | Urea | BUN | |
| G1 | 8.51 ± 0.42 ab | 3.87 ± 0.26 ab | 4.64 ± 0.57 a | 0.69 ± 0.08 b | 50.68 ± 2.27 d | 19.68 ± 1.34 bc |
| G2 | 6.25 ± 0.19 d | 2.85 ± 0.19 c | 3.41 ± 0.31 b | 1.55 ± 0.09 a | 97.56 ± 3.48 a | 27.76 ± 1.63 a |
| G3 | 7.03 ± 0.18 c | 3.25 ± 0.30 bc | 3.78 ± 0.32 ab | 0.85 ± 0.05 b | 65.34 ± 5.39 b | 22.07 ± 2.02 bc |
| G4 | 7.36 ± 0.23 bc | 3.31 ± 0.20 bc | 4.05 ± 0.22 a | 0.79 ± 0.05 bc | 63.53 ± 3.18 b | 22.43 ± 1.34 bc |
| G5 | 8.03 ± 0.24 abc | 3.48 ± 0.14 abc | 4.55 ± 0.34 a | 0.72 ± 0.04 c | 56.96 ± 1.96 c | 21.12 ± 1.25 bc |
| G6 | 8.70 ± 0.25 a | 4.28 ± 0.23 a | 4.41 ± 0.45 a | 0.69 ± 0.05 c | 51.04 ± 3.01 cd | 21.26 ± 1.13 bc |
| G7 | 7.54 ± 0.34 abc | 3.06 ± 0.19 bc | 4.48 ± 0.29 a | 0.77 ± 0.05 bc | 62.35 ± 6.95 b | 20.77 ± 1.28 bc |
G1–G7: Experimental groups see materials and methods; Section 2.6, BUN: Blood urea nitrogen, a, b, c and d: No significant difference (p > 0.05) between any two means within the same column with the same superscripted letters.
Effects of oral administration of probiotic-enriched FCM combined with S. officinalis on antioxidant biomarkers in Streptozotocin-induced diabetes in rats (mean ± SE), n = 6.
| Group | Antioxidant Biomarkers | |||
|---|---|---|---|---|
| GSH (µg dL−1) | MDA (n mol mL−1) | CAT (U L−1) | SOD (U L−1) | |
| G1 | 62.51 ± 4.38 ab | 21.25 ± 1.33 c | 56.96 ± 5.64 bc | 83.63 ± 1.85 b |
| G2 | 44.91 ± 2.66 d | 36.43 ± 4.37 a | 39.53 ± 2.92 d | 56.14 ± 0.51 e |
| G3 | 50.40 ± 1.37 c | 23.57 ± 1.85 c | 50.21 ± 4.59 c | 70.17 ± 0.64 d |
| G4 | 49.88 ± 4.80 c | 19.65 ± 3.59 c | 64.92 ± 4.30 ab | 79.31 ± 0.84 c |
| G5 | 65.13 ± 4.48 ab | 16.14 ± 1.98 d | 65.65 ± 5.86 ab | 84.79 ± 0.74 b |
| G6 | 69.06 ± 5.08 a | 15.05 ± 2.78 d | 75.08 ± 5.45 a | 91.54 ± 0.79 a |
| G7 | 50.96 ± 7.45 c | 27.32 ± 2.74 b | 56.88 ± 6.22 bc | 70.17 ± 0.46 d |
G1–G7: Experimental groups see materials and methods; Section 2.6, GSH: Reduced glutathione, MDA: Malonaldehyde, CAT: Catalase, SOD: Superoxide dismutase, a, b, c, d and e: No significant difference (p > 0.05) between any two means within the same column with the same superscripted letters.
The severity of histopathological alteration in rat pancreas underlying structure of different experimental groups treated by probiotic-enriched FCM combined with S. officinalis.
| G1 | G2 | G3 | G4 | G5 | G6 | G7 | |
|---|---|---|---|---|---|---|---|
| Atrophy in islets of Langerhans | – | +++ | – | + | + | – | – |
| Necrobiosis in acini | – | ++ | + | – | – | – | – |
| Interlobular fibrosis | – | +++ | + | + | – | – | – |
G1–G7: Experimental groups see materials and methods; Section 2.6, +++ = severe, ++ = moderate, + = mild, – = nil.
Figure 1Histopathological findings of rats’ pancreas of the experimental groups (Hematoxylin-Eosin, HE; ×16). (G1): Showing normal histological structure of the islets of Langerhans cells as endocrine portion with the acini and duct system of the exocrine (×16). (G2) (a,b): Showing interlobular fibrosis with atrophy of islets of Langerhans and the acini. (G3): Showing intact islet of Langerhans cells with fine fibrosis between the lobules. (G4): Showing atrophy in islets of Langerhans cells with necrobiosis in the acini. (G5–G7): Showing normal histological structure of both islet of Langerhans cells and acini.